Exosomes in Alzheimer’s Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics
Open accessThe DOI matches its Crossref record; 151 of the 154 references it cites were found in a registry or an index.
Abstract
Exosomes (EXOs) were given attention as an extracellular vesicle (EV) with a pivotal pathophysiological role in the development of certain neurodegenerative disorders (NDD), such as Parkinson’s and Alzheimer’s disease (AD). EXOs have shown the potential to carry pathological and therapeutic cargo; thus, researchers have harnessed EXOs in drug delivery applications. EXOs have shown low immunogenicity as natural drug delivery vehicles, thus ensuring efficient drug delivery without causing significant adverse reactions. Recently, EXOs provided potential drug delivery opportunities in AD and promising future clinical applications with the diagnosis of NDD and were studied for their usefulness in disease detection and prediction prior to the emergence of symptoms. In the future, the microfluidics technique will play an essential role in isolating and detecting EXOs to diagnose AD before the development of advanced symptoms. This review is not reiterative literature but will discuss why EXOs have strong potential in treating AD and how they can be used as a tool to predict and diagnose this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Exosomes exhibit low immunogenicity and high biocompatibility, thereby minimizing the risk of immune responses and facilitating efficient delivery to the brain [89, 90].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gercel-Taylor, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,288 · cited 2×
“For 218 of the 467 mature microRNAs examined, microRNA from ovarian tumor cells and EXOs from similar individuals were positive [101].”
BackgroundRetractedCirculating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186 · cited 1×
“The great diagnostic potential of EXOs lies in the fact that these nanosized vesicles have a specific profile of biomolecule content from the cell of origin, similar to proteins, nucleic acids, and lipids; they act as a “fingerprint” or a “signature” of parent cells and can reflect the pathological conditions when cha…”
BackgroundIsolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766 · cited 2×
“Immuno-Isolation • High-purity isolation • Knowledge of the exosomal surface components is a challenge in this method • Scale-up [56,61]”
MethodDelivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930 · cited 3×
“For example, modified surface proteins with overexpressed Lamp2b bound to the neuron-specific rabies virus glycoprotein (RVG) peptide were found to enhance CNS penetration and targeting capabilities [47].”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · cited 1×
“Recent studies prove that soluble Aβ oligomeric forms can be a potential player in AD progression [24].”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“Tetraspanins organize the multimolecular membrane complexes, cell adhesion, fusion, signaling, and metastatic processes [50,51], and they were also reported to serve as a facilitative component in infection processes, promoting viral penetration and exit [52].”
BackgroundThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Introduction to NF-κB: players, pathways, perspectives
Gilmore, T. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209954 · Cited by 2,222 · cited 1×
“NF-κB is found almost in all cell types and is involved in cellular signaling and stimuli such as cytokines, stress, free radicals, oxidized-LDL, and microbial antigens [87].”
BackgroundExosomes: biogenesis, biologic function and clinical potential
Zhang, Y., Liu, Y., Liu, H., & Tang, W. H. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0282-2 · Cited by 2,119
Cited by
Applications of Phyto-Nanotechnology for the Treatment of Neurodegenerative Disorders
Bhattacharya, T., Soares, G. A. B. E., Chopra, H., Rahman, M. M., Hasan, Z., Swain, S. S., & Cavalu, S. (2022) · Materials · doi:10.3390/ma15030804 · Cited by 259
“Exosomes, which are naturally produced by human cells, are emerging as a new generation of highly protective nanoplatforms for efficient drug delivery [172].”
BackgroundSelf-citationUnderstanding exosomes: Part 2—Emerging leaders in regenerative medicine
Miron, R. J., Estrin, N. E., Sculean, A., & Zhang, Y. (2024) · Periodontology 2000 · doi:10.1111/prd.12561 · Cited by 98
The Exosome-Mediated PI3K/Akt/mTOR Signaling Pathway in Neurological Diseases
Iranpanah, A., Kooshki, L., Moradi, S. Z., Saso, L., Fakhri, S., & Khan, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031006 · Cited by 64
Production and Utility of Extracellular Vesicles with 3D Culture Methods
Ester, M. C., & Day, R. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020663 · Cited by 74
Exosomes in brain diseases: Pathogenesis and therapeutic targets
Si, Q., Wu, L., Pang, D., & Jiang, P. (2023) · MedComm · doi:10.1002/mco2.287 · Cited by 70
Kochman, U., Sitka, H., Kuźniar, J., Czaja, M., Kozubek, P., Beszłej, J. A., & Leszek, J. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05417-z · Cited by 60
Exosome: From biology to drug delivery
Baruah, H., Sarma, A., Basak, D., & Das, M. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01515-y · Cited by 57
Nasal delivery of neurotherapeutics via nanocarriers: Facets, aspects, and prospects
Rajput, A., Pingale, P., & Dhapte-Pawar, V. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.979682 · Cited by 58
Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges
Cano, A. C., Muñoz-Morales, Á., Sánchez‐López, E., Ettcheto, M., Souto, E. B., Camins, A., Boada, M., & Ruiz, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010298 · Cited by 53
“Several authors have explored the therapeutic potential of exosomes in AD [138].”
BackgroundEfficient methods of isolation and purification of extracellular vesicles
Kim, T.-W., Hong, J. W., & Lee, L. P. (2025) · Nano Convergence · doi:10.1186/s40580-025-00509-x · Cited by 53
“Additionally, exosomes can be effectively employed as drug delivery systems [57,58].”
Nanomedicines in the Management of Alzheimer’s Disease: Current View and Future Prospects
Chopra, H., Bibi, S., Singh, I., Kamal, M. A., Islam, F., Alhumaydhi, F. A., Emran, T. B., & Cavalu, S. D. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879114 · Cited by 49
Self-citationAttia, M. S., Yahya, A. S., Abdelmonaem, N., & Sabry, S. A. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.01.009 · Cited by 45
“Additionally, exosomes counteract A b -induced disruptions and apoptosis in the genetically modified neuroblastoma cell line (N2a cells); this scavenging effect is due to the binding of its gly-cosphingolipid with A b -glycan (Soliman et al., 2021).”
Self-citationWu, J., Yuan, M., Shen, J., Chen, Y., Zhang, R., Chen, X., Wang, H., Yin, Z., Zhang, X., Liu, S., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154229 · Cited by 43
Unveiling the Complex Role of Exosomes in Alzheimer’s Disease
Sun, M., & Chen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466821 · Cited by 39
“13 Exosomes associated with AD were first discovered while studying the buildup of APP cleavage in MVBs, 14,15 which are considered as progenitors of exosomes.”
BackgroundThe emerging double-edged sword role of exosomes in Alzheimer’s disease
Liang, T., Wu, Z., Li, J., Wu, S., Shi, W., & Wang, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1209115 · Cited by 37
“There is increasing experimental evidence showing that exosomes play indispensable roles in the formation and dissemination of these two major pathological hallmarks (Soliman et al., 2021).”
BackgroundRole of siRNA-based nanocarriers for the treatment of neurodegenerative diseases
Mishra, N., Ashique, S., Garg, A., Rai, V. K., Dua, K., Goyal, A. K., & Bhatt, S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.003 · Cited by 39
Biomarkers associated with the pathogenesis of Alzheimer’s disease
Wang, H., Sun, M., Li, W., Liu, X., Zhu, M., & Qin, H. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1279046 · Cited by 41
“UrolithinA treatment also enhanced memory and reduced tau hyperphosphorylation in 3xTgAD mice (Soliman et al., 2021).”
BackgroundSong, S., Lee, J. U., Jeon, M. J., Kim, S., Lee, C.-N., & Sim, S. J. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115269 · Cited by 34
Herman, M., Randall, G. W., Spiegel, J. L., Maldonado, D. J., & Simoes, S. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2022.0387 · Cited by 34
Exosomes in Parkinson: Revisiting Their Pathologic Role and Potential Applications
Ouerdane, Y., Hassaballah, M. Y., Nagah, A., Ibrahim, T. M., Mohamed, H. A. H., El-Baz, A., & Attia, M. S. (2022) · Pharmaceuticals · doi:10.3390/ph15010076 · Cited by 33
“EXOs succeed in drawing an in-depth look for their future usage in clinical studies for AD [198].”
BackgroundSelf-citationGomes, C., Sequeira, C., Likhite, S. B., Dennys, C. N., Kolb, S. J., Shaw, P. J., Vaz, A. R., Kaspar, B. K., Meyer, K., & Brites, D. M. T. O. (2022) · Cells · doi:10.3390/cells11071186 · Cited by 33
Ye, M., Wang, J., Pan, S., Zheng, L., Wang, Z. P., & Zhu, X. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.005 · Cited by 31
“The exosomebased cargo delivery system functions in intercellular communication through endocytosis and receptor-ligand interactions, and subsequently participates in regulating a variety of physiological and pathological processes.(21,22) In particular, compared with healthy cells, the cancer cells release more exoso…”
BackgroundCustodia, A., Romaus‐Sanjurjo, D., Aramburu-Núñez, M., Álvarez-Rafael, D., Vázquez‐Vázquez, L., Camino-Castiñeiras, J., Leira, Y., Peleteiro, J. M. P., Aldrey, J. M., Sobrino, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158082 · Cited by 33
Zhang, Y., Bi, K., Zhou, L., Wang, J., Huang, L., Sun, Y., Peng, G., & Wu, W. (2024) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s471174 · Cited by 46
Exosomes: A missing link between chronic systemic inflammation and Alzheimer’s disease?
Ozansoy, M., Mikati, H., Velioğlu, H. A., & Yuluğ, B. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114161 · Cited by 30
Abdelkhalek, A. S., Attia, M. S., & Kamal, M. A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230228120416 · Cited by 26
Self-citationHSV-1 infection induces phosphorylated tau propagation among neurons via extracellular vesicles
Protto, V., Miteva, M. T., Iannuzzi, F., Marcocci, M. E., Puma, D. D. L., Piacentini, R., Belli, M., Sansone, L., Pietrantoni, A., Grassi, C., et al. (2024) · mBio · doi:10.1128/mbio.01522-24 · Cited by 28
“Interestingly, exo were shown to carry misfolded proteins such as Aβ oligomers and tau protein in AD (15).”
BackgroundRecent advances in isolation and detection of exosomal microRNAs related to Alzheimer's disease
Pishbin, E., Sadri, F., Dehghan, A., Kiani, M. J., Hashemi, N., Zare, I., Mousavi, P., & Rahi, A. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115705 · Cited by 25
Afram, E., Lauritzen, I., Bourgeois, A., Manaa, W. E., Duplan, E., Chami, M., Valverde, A., Bauer, C., Pardossi‐Piquard, R., & Checler, F. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04737-4 · Cited by 26
Kanojia, N., Thapa, K., Kaur, G., Sharma, A., Puri, V., & Verma, N. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104074 · Cited by 21
Chimal‐Vega, B., Maldonado-Arvizu, J. E., Hernández-Avalos, A. D., Díaz‐Villanueva, J. F., Ávila‐Barrientos, L. P., & García‐González, V. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5010011 · Cited by 20
“…exosomes with miR-34a exert effects such as inflammation, glucose tolerance, and insulin resistance [92,101]. miR34a has been shown to be upregulated in visceral fat of obese subjects, and miR-34a KO mice displayed protection against obesity-related glucose intolerance and insulin [92,101].”
InfluentialWeber, J. I., Rodrigues, A., Valério-Bolas, A., Nunes, T., Carvalheiro, M., Antunes, W., Alexandre‐Pires, G., da Fonseca, I. P., & Santos-Gomes, G. M. (2023) · Cells · doi:10.3390/cells12081101 · Cited by 19
“Cells 2023, 12, 1101 3 of 25 Several studies have already evaluated the use of exosomes in the treatment of diseases such as COVID-19 [16–18], carcinomas [19], stroke [20], Parkinson’s [21], and Alzheimer’s [22].”
BackgroundMultiparametric Biosensors for Characterizing Extracellular Vesicle Subpopulations
Shaabani, N., Meira, S. R., Marcet‐Palacios, M., & Kulka, M. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00207 · Cited by 19
Meldolesi, J. (2022) · Biomedicines · doi:10.3390/biomedicines10010105 · Cited by 17
Salminen, A. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16450 · Cited by 15
“There are many studies indicating that an increase in exosomal trafficking is associated with AD pathology (Soliman et al., 2021).”
Nanotechnology for Biomedical Applications
Pasika, S. R., Bulusu, R., Rao, B. V. K., Kommineni, N., Bolla, P. K., Kala, S. G., & Godugu, C. (2023) · Springer eBooks · doi:10.1007/978-981-19-7963-7_11 · Cited by 18
Huang, S., Nie, Y., Qin, J., Wen, M., Wang, Q., Xie, F., Song, F., & Yang, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-79558-x · Cited by 13
Shahlaei, M., Afkhami, H., Ahmadieh-Yazdi, A., Mirmazloumi, S. H., Sahraei, S. S., Akbari, M., Yang, P., Manoochehri, H., Tanzadehpanah, H., Mahaki, H., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118548 · Cited by 22
Wu, J., Zhu, S., Zhao, C., & Xu, X. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220202120638 · Cited by 13
Pala, M., & Yılmaz, Ş. G. (2025) · Neural Plasticity · doi:10.1155/np/9581369 · Cited by 12
“Peptides involved in AD processes were discovered in EXOs via the cleavage of APP sequences [27].”
Gao, T., Chu, Q., Xing, X., Liu, Y., Fu, S., & Liu, D. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s588836 · Cited by 20
“163 Specifically for intranasal-to-brain drug delivery, exosomes are a focal point of research aimed at enhancing targeting precision and delivery efficiency to the brain.”
Spheroid-Exosome-Based Bioprinting Technology in Regenerative Medicine
Lee, H.-Y., & Lee, J. W. (2024) · Journal of Functional Biomaterials · doi:10.3390/jfb15110345 · Cited by 10
Abdi, S. M. Y., Bakri, S. S. M. A., & Nordin, N. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01598-x · Cited by 8
“Because of their nanometer-sized and permeability, stem cell-derived exosomes may penetrate the BBB and are involved in various signalling processes, offering insight into the development and management of AD [76].”
Afzal, M., Hameed, H., Paiva‐Santos, A. C., Saleem, M., Hameed, A., & Ahmad, S. M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177199 · Cited by 9
Randhawa, S., Saini, T. C., Bathla, M., Bhardwaj, R., Dhiman, R., & Acharya, A. (2025) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.16.44 · Cited by 9
Potential Role of Extracellular Vesicles in Mediating Effects of Exercise on Brain Function
Moon, H. Y., & van Praag, H. (2025) · Advances in neurobiology · doi:10.1007/978-981-95-0066-6_8 · Cited by 8
Bhattacharya, A., & Chatterji, U. (2024) · Discover Oncology · doi:10.1007/s12672-024-01262-z · Cited by 7
Saadh, M. J., Ahmed, H. H., Sanghvi, G. V., Isa, M. Z. B. A., Singh, P. A., Kaur, K., Kumar, M. R., & Husseen, B. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155984 · Cited by 7
High-throughput exosome isolation based on bidirectional flow control through nanoporous membrane
Kim, G., Kim, K., Seo, M., Kim, T., & Chun, H. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.136233 · Cited by 6
Extravaganza of Nanobiotechnology in the Diagnosis and Treatment of Dementia Patients
Bhattacharya, S. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1385272827666221027103050 · Cited by 6
Understanding the Intricate Role of Exosomes in Pathogenesis of Alzheimer’s Disease
Chauhan, S., Behl, T., Sehgal, A., Singh, S., Sharma, N., Gupta, S., Albratty, M., Najmi, A., Meraya, A. M., & Alhazmi, H. A. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00621-4 · Cited by 6
“The assessment of olfactory function in conjunction with amyloid-β in neuronal derived exosomes might lead to novel ways for estimating the probability of MCI leading to AD (Soliman et al. 2021).”
BackgroundYuan, G., Lian, Y., Wang, J., Yong, T., Gao, H., Wu, H., Tao, Y., & Wang, C. (2023) · Plant Cell Reports · doi:10.1007/s00299-023-03057-y · Cited by 6
Extracellular Vesicles: A New Approach to Study the Brain’s Neural System and Its Diseases
Afridi, S., Sharma, P., Choudhary, F., Rizwan, A., Nizam, A., Parvez, A., & Farooqi, H. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01271-3 · Cited by 6
“It has been witnessed that hyperphosphorylated tau protein from neuro fi brillary tangles (NFT) accumulates in the brain and causes memory loss in Alzheimer ’ s patients [33].”
Therapeutic and Diagnostic Roles of MSC‐Derived Exosomes in Alzheimer's Disease
Patil, V. S., Parekh, B. K., Sharma, A., Farah, H., Renuka Jyothi, S., Mishra, S. S., Nanda, A., Al-Hasnaawei, S., & Kumar‐Mishra, M. (2025) · Brain and Behavior · doi:10.1002/brb3.71112 · Cited by 8
“Convergence across studies will require standardized collection, isolation, and characterization protocols to clarify the diagnostic meaning of these morphological metrics (Soliman et al. 2021 ; Yakubovich et al. 2022 ).”
Prabhu, M. R., Upadhya, D., Madhyastha, H., Naha, A., Perumalsamy, H., Sunderraj, S., Dubey, A., Rahimi, S., Balusamy, S. R., & Hebbar, S. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04058-1 · Cited by 9
“The main disadvantage of the active loading strategy is that it weakens the structural integrity of MEVs and reduces the number of proteins on their surfaces, thus preventing them from functioning [233].”
Nanobiotechnology: A New Frontier for Brain Disorders
Picone, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179603 · Cited by 5
“Recent work on EXOs has pointed out various aspects related to their roles in the pathogenesis, diagnosis and treatment of Alzheimer’s disease (AD) [14].”
BackgroundInfluentialUnveiling Exosome Potential: Transforming Treatments for Neurodegeneration
Tiwari, A. K., Singh, B. K., Singh, G. K., Meena, J., Agrawal, A. K., Kumar, S., & Modi, G. P. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00096 · Cited by 6
Zhao, X., Zheng, Y., Cai, X. T., Yao, Y., & Qin, D. (2026) · Pharmaceuticals · doi:10.3390/ph19010092 · Cited by 6
“…digital PCR (ddPCR), which partitions samples into thousands of droplets to enable precise, absolute quantification of low-abundance targets in EV-enriched samples, exhibiting superior performance in CSF lncRNA profiling for ALS since 2015 with reduced batch effects via spike-in controls [140].”
Preetam, S., Mishra, R., Alghamdi, S. S., Aslam, A., Thapliyal, S., Rustagi, S., Govindarajan, R. K., Pandit, S., Bora, J., Rabbee, M. F., et al. (2026) · Microchimica Acta · doi:10.1007/s00604-026-07962-3 · Cited by 5
“Together, they underscore the translational potential of microfluidic platforms in bringing AD diagnostics closer to POC clinical adoption (Table 3 ). of amyloid and tau fragments, with microfluidic platforms enabling multiplexed detection and staging potential [ 17] (Fig.”
Bridging prion biology and Alzheimer’s disease: from pathogenic seeds to precision therapeutics
Wang, W., Feng, Z., Shu, L., Hu, Y., Chen, Y., Zhang, B., & Huang, H. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1660151 · Cited by 3
Aydemir, M., Gacar, G., HALBUTOĞULLARI, Z. S., Duruksu, G., Öztürk, A., Altuntaş, C., & Yazır, Y. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103035 · Cited by 3
Mushtaq, T., Hameed, H., Paiva‐Santos, A. C., Tariq, U., & Hameed, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05189-6 · Cited by 2
“Exosomes contribute significantly to the pathogenesis of AD, particularly in the formation and spread of amyloid-beta (Aβ) plaques [14].”
Extracellular vesicles in Niemann pick disease type C: current knowledge and future opportunities
Hawthorne, S. C. B., Sandau, U. S., & Saugstad, J. A. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1730603 · Cited by 2
Targeted Nanodelivery of WGX50 and Curcumin via Gold Nanoparticles for Alzheimer's Therapy
Lodhi, M. S., Maisam, M., Khan, M. T., Bibi, A., Wei, D., & Mou, K. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71045 · Cited by 2
Vesicular Transport and Amyloids: The Growing Relationship
Upadhyay, A. (2024) · Biologics · doi:10.3390/biologics4040023 · Cited by 1
Kangarshahi, B. M., Naghib, S. M., Kashani, G. K., & Mozafari, M. R. (2025) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2025.2561599 · Cited by 1
Andreadou, E. G., Evangelopoulou, E., Tsolaki, M., Tsamesidis, I., Pessach, I., & Mitka, S. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080808 · Cited by 2
“Favorable short-term safety and low immunogenicity in preclinical and early clinical studies; long-term toxicity, biodistribution, and immune effects remain insufficiently defined [30,55,70,71].”
Noble Metal Nanoparticle‐Based Aptasensors: A Powerful Tool for Exosomal Detection
Sun, J., Hu, W., Xu, N., Makris, J., Spadavecchia, F., & Wang, H. (2024) · Advanced Sensor Research · doi:10.1002/adsr.202400002 · Cited by 1
Gorji, F. S., Mahdavian, S. F., Khodashenas, S., Kiasari, Z. R., Valadan, R., Khalili, S., & Mahdavi, M. R. (2024) · The Protein Journal · doi:10.1007/s10930-024-10234-9 · Cited by 1
“They have been used as a vehicle in the transport of various bioactive molecules across the BBB [29], such as siRNA for the treatment of MS and Alzheimer's [30, 31], and miRNA for morphine relapse.”
Nanofluidic Technologies for Drug Screening and Drug Delivery
Kazoe, Y., Sueyoshi, K., Seetasang, S., & Xu, Y. (2023) · Advanced clinical pharmacy - research, development and practical applications/Advanced clinical pharmacy - research, development and practical applications · doi:10.1007/978-3-031-26908-0_14 · Cited by 1
Sandal, P., Arora, S., & Gugulothu, D. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-29052-7.00005-2
Exploring extracellular vesicles: Understanding exosomes and beyond
Laxmi, L., Golmei, P., Gugulothu, D. B., Sharma, A., & Kumar, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-29052-7.00002-7
Scouting Biomarkers for Alzheimer’s Disease via Network Analysis of Exosome Proteomics Data
Sagonas, A., Apostolakou, A. E., Litou, Z. I., Antonelou, M. H., & Iconomidou, V. A. (2025) · BioMedInformatics · doi:10.3390/biomedinformatics5020019
“Exosomes may carry components like N-APP, which interact with DR6, thereby promoting neurodegeneration, as suggested by recent findings [90].”
The Treatment of Neurological Disease via Green Metallic Nanoparticles
Wananje, P. U., Patil, A. S., Wakure, B. S., & Pimpale, S. V. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00497
Exosomal cytokine profile on lipopolysaccharide-induced acute lung injury in mice
Liang, J., He, Y., Chen, X., Wang, L., & Cai, S. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10610-4
“Given their presence in various body fluids—including serum, BALF, urine, and ascitic fluid (Soliman et al. 2021 )—exosomes may act as critical propagators of injury beyond the lung, potentially contributing to MODS in severe cases.”
Blood-based emerging biomarkers in early detection and diagnosis of Alzheimer’s disease
Anand, T., & Kumar, A. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.01.002
Hawthorne, S. C. B., Sandau, U. S., McFarland, T. J., Berry‐Kravis, E., & Saugstad, J. A. (2026) · Journal of Extracellular Biology · doi:10.1002/jex2.70136
“As such, EVs have been implicated in the pathology of both neurodegenerative (Soliman et al. 2021 ; Rastogi et al. 2021 ) and lysosomal storage disorders (Gleason et al. 2021 ; Hegeman et al. 2022 ).”
Anti-aging Concepts: Adipose Tissue as a Therapeutic Target in Anti-aging Medicine
Knoedler, S., & Prantl, L. (2026) · Springer eBooks · doi:10.1007/978-3-032-01711-6_17
Hotspots and trends of microglia in ischemic stroke: A bibliometric analysis from 1998 to 2024
Ma, L., Cao, J.-P., Li, J., Fan, Z., Chen, S., Li, J., Lin, X., & Guo, Y. (2026) · Medicine · doi:10.1097/md.0000000000048993
“[43] Enhanced microglial cell glycolysis induced by hypoxic environment forms a multidimensional neuroinflammatory regulatory network through HIF1 α -mediated metabolic reprogramming, activation of PKM2-STAT3 signaling axis, and lactate-driven exosome release.”
Patwekar, M., Patwekar, F., Kari, Z. A., Mohammed, A., & Sharma, R. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156594
AYDIN, A. C. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06191-2
Metadata
- Authors
- Soliman, H. M., Ghonaim, G. A., Gharib, S. M., Chopra, H., Farag, A. K., Hassanin, M. H., Nagah, A., Emad-Eldin, M., Hashem, N. E., Yahya, G., Emam, S. E., Hassan, A. E. A., & Attia, M. S.
- Affiliations
- Zagazig University (EG)
- Chitkara University (IN)
- Corresponding author
- Attia, Mohamed S.
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-10-06
- Volume
- 22
- Issue
- 19
- Pages
- 10794
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8509246
- OpenAlex
- W3202186439
- Cited by
- 81
- References
- 154
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 19 · 2023: 17 · 2022: 14 · 2021: 1
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- exosomes, Alzheimer's disease, extracellular vesicles, drug delivery, neurodegenerative diseases, biomarkers, early diagnosis, microfluidics, exosome isolation, immunogenicity, therapeutics
- MeSH terms
- Alzheimer Disease, Animals, Humans, Exosomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.